Compare Archer Aviation Inc (ACHR) vs AstraZeneca plc (AZN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Archer Aviation Inc vs AstraZeneca plc — how do they compare? Archer Aviation Inc trades at $6.34 (market cap $5.23B), while AstraZeneca plc trades at $158.59 (market cap $248.14B). The key difference: AstraZeneca plc is far larger — about 47.4× Archer Aviation Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Archer Aviation Inc pays none. Which is the better fit depends on your goals.
| ACHR | AZN | |
|---|---|---|
Market Cap | $5.23B | $248.14B |
Sector | Industrials | Health |
52-Week High | $13.64 | $209.48 |
52-Week Low | $4.44 | $147.06 |
Enterprise Value | $3.79B | $275.41B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Archer Aviation (ACHR) trades at $6.30, up 0.64% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company reported a Q2 2026 revenue beat but sustained heavy losses, with a net income margin of -11,589.86% in 2026. Recent news highlights a strategic deal with Boeing to acquire three businesses, broadening its defense and AI aviation portfolio, which fueled a significant stock rally.
The outlook remains speculative with high execution risks amid substantial cash burn, but analyst sentiment is strongly bullish (77.78% buy ratings) due to regulatory progress and Boeing's backing. Key risks include dilution from equity offerings, certification delays, and profitability challenges in the nascent eVTOL market.
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Archer Aviation Inc
Archer Aviation develops electric vertical takeoff and landing (eVTOL) aircraft for urban air mobility. Its flagship, Midnight aircraft, is designed for air taxi services, aiming to transform urban travel with sustainable aviation.
Read more on ACHR →About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →
